Pharmacokinetics of ofloxacin and levofloxacin for prevention and treatment of multidrug-resistant tuberculosis in children

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 5, 2014, Pages 2948-2951

  Thee, S ^a,b   Garcia Prats, A J ^a   McIlleron, H M ^c   Wiesner, L ^c   Castel, S ^c   Norman, J ^c   Draper, H R ^a   Van Der Merwe, P L ^a   Hesseling, A C ^a   Schaaf, H S ^a  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOFLOXACIN; OFLOXACIN; TUBERCULOSTATIC AGENT;

AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG EXPOSURE; FEMALE; HUMAN; INFANT; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; NEWBORN; PRESCHOOL CHILD; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION; TUBERCULOSIS CONTROL; ADOLESCENT; BLOOD; PROSPECTIVE STUDY; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ADOLESCENT; ANTITUBERCULAR AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; LEVOFLOXACIN; MALE; OFLOXACIN; PROSPECTIVE STUDIES; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84898640724     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02755-13     Document Type: Article

References (29)

1. WHO. 2012. Global Tuberculosis Report 2012. World Health Organization, Geneva, Switzerland. http://apps.who.int/iris/bitstream/10665/75938/1/ 9789241564502-eng.pdf.
2. Seddon JA, Hesseling AC, Marais BJ, Jordaan A, Victor T, Schaaf HS. 2012. The evolving epidemic of drug-resistant tuberculosis among children in Cape Town, South Africa. Int. J. Tuberc. Lung Dis. 16:928-933. http://dx.doi.org/10. 5588/ijtld.11.0679.
3. Pranger AD, Alffenaar JW, Aarnoutse RE. 2011. Fluoroquinolones, the cornerstone of treatment of drug-resistant tuberculosis: a pharmacokinetic and pharmacodynamic approach. Curr. Pharm. Des. 17:2900-2930. http://dx.doi.org/10. 2174/138161211797470200.
4. Bethell DB, Day NP, Dung NM, McMullin C, Loan HT, Tam DT, Minh LT, Linh NT, Dung NQ, Vinh H, MacGowan AP, White LO, White NJ. 1996. Pharmacokinetics of oral and intravenous ofloxacin in children with multidrug-resistant typhoid fever. Antimicrob. Agents Chemother. 40: 2167-2172.
5. Chien S, Wells TG, Blumer JL, Kearns GL, Bradley JS, Bocchini JA, Jr, Natarajan J, Maldonado S, Noel GJ. 2005. Levofloxacin pharmacokinetics in children. J. Clin. Pharmacol. 45:153-160. http://dx.doi.org/10.1177/ 0091270004271944.
6. Mase S, Jereb J, Daley CL, Fred D, Loeffler A, Peloquin C. 2011. Pharmacokinetics of levofloxacin in pediatricMDRTB cases and contacts, Federated States of Micronesia. Am. J. Respir. Crit. Care Med. 183:A1837. http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1-MeetingAbstracts.A1837.
7. WHO. 2006. Guidance for national tuberculosis programmes on the management of tuberculosis in children. WHO/HTM/TB/2006.371. World Health Organization, Geneva, Switzerland.
8. Meredith SA, Smith PJ, Norman J, Wiesner L. 2012. An LC-MS/MS method for the determination of ofloxacin in 20 ml human plasma. J. Pharm. Biomed. Anal. 58:177-181. http://dx.doi.org/10.1016/j.jpba.2011.09.030.
9. Sirgel FA, Warren RM, Streicher EM, Victor TC, van Helden PD, Bottger EC. 2012. gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis. J. Antimicrob. Chemother. 67:1088-1093. http://dx.doi.org/10.1093/jac/dks033.
10. Ji B, Truffot-Pernot C, Grosset J. 1991. In vitro and in vivo activities of sparfloxacin (AT-4140) against Mycobacterium tuberculosis. Tubercle 72: 181-186. http://dx.doi.org/10.1016/0041-3879(91)90004-C.
11. Rodríguez JC, Ruiz M, Lopez M, Royo G. 2002. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. Int. J. Antimicrob. Agents 20:464-467. http://dx.doi.org/10.1016/ S0924-8579(02)00239-X.
12. JI B, Lounis N, Truffot-Pernot C, Grosset J. 1995. In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 39:1341-1344. http://dx.doi.org/10.1128/AAC.39.6.1341.
13. Fridericia LS. 2003. The duration of systole in an electrocardiogram in normal humans and in patients with heart disease. Ann. Noninvasive Electrocardiol. 8:343-351. http://dx.doi.org/10.1046/j.1542-474X.2003.08413.x.
14. Lode H, Hoffken G, Olschewski P, Sievers B, Kirch A, Borner K, Koeppe P. 1987. Pharmacokinetics of ofloxacin after parenteral and oral administration. Antimicrob. Agents Chemother. 31:1338-1342. http://dx.doi.org/10.1128/AAC.31.9. 1338.
15. Yuk JH, Nightingale CH, Quintiliani R, Sweeney KR. 1991. Bioavailability and pharmacokinetics of ofloxacin in healthy volunteers. Antimicrob. Agents Chemother. 35:384-386. http://dx.doi.org/10.1128/AAC.35.2.384.
16. Malerczyk V, Verho M, Korn A, Rangoonwala R. 1987. Relative bioavailability of ofloxacin tablets in comparison to oral solution. Curr. Med. Res. Opin. 10:514-520. http://dx.doi.org/10.1185/03007998709108959.
17. Peloquin CA, Nitta AT, Burman WJ, Brudney KF, Miranda-Massari JR, McGuinness ME, Berning SE, Gerena GT. 1996. Low antituberculosis drug concentrations in patients with AIDS. Ann. Pharmacother. 30:919-925.
18. Gurumurthy P, Ramachandran G, Hemanth Kumar AK, Rajasekaran S, Padmapriyadarsini C, Swaminathan S, Venkatesan P, Sekar L, Kumar S, Krishnarajasekhar OR, Paramesh P. 2004. Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis. Clin. Infect. Dis. 38:280-283. http://dx.doi.org/10.1086/380795.
19. Graham SM, Bell DJ, Nyirongo S, Hartkoorn R, Ward SA, Molyneux EM. 2006. Low levels of pyrazinamide and ethambutol in children with tuberculosis and impact of age, nutritional status, and human immunodeficiency virus infection. Antimicrob. Agents Chemother. 50:407-413. http://dx.doi.org/10.1128/AAC.50.2. 407-413.2006.
20. Stambaugh JJ, Berning SE, Bulpitt AE, Hollender ES, Narita M, Ashkin D, Peloquin CA. 2002. Ofloxacin population pharmacokinetics in patients with tuberculosis. Int. J. Tuberc. Lung Dis. 6:503-509.
21. Chulavatnatol S, Chindavijak B, Chierakul N, Klomsawat D. 2003. Pharmacokinetics of ofloxacin in drug-resistant tuberculosis. J. Med. Assoc. Thai. 86:781-788.
22. Peloquin CA, Hadad DJ, Molino LP, Palaci M, Boom WH, Dietze R, Johnson JL. 2008. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob. Agents Chemother. 52:852-857. http://dx.doi.org/10.1128/AAC.01036-07.
23. Anderson BJ, Holford NH. 2013. Understanding dosing: children are small adults, neonates are immature children. Arch. Dis. Child. 98:737-744. http://dx.doi.org/10.1136/archdischild-2013-303720.
24. Ginsburg AS, Grosset JH, Bishai WR. 2003. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect. Dis. 3:432-442. http://dx.doi.org/10.1016/S1473- 3099(03)00671-6.
25. Shandil RK, Jayaram R, Kaur P, Gaonkar S, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharath S, Balasubramanian V. 2007. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob. Agents Chemother. 51:576-582. http://dx.doi.org/10.1128/AAC.00414- 06.
26. Schentag JJ, Gilliland KK, Paladino JA. 2001. What have we learned from pharmacokinetic and pharmacodynamic theories? Clin. Infect. Dis. 32(Suppl 1):S39-S46. http://dx.doi.org/10.1086/319375.
27. Seddon JA, Hesseling AC, Willemse M, Donald PR, Schaaf HS. 2012. Culture-confirmed multidrug-resistant tuberculosis in children: clinical features, treatment, and outcome. Clin. Infect. Dis. 54:157-166. http://dx.doi.org/10.1093/cid/cir772.
28. Seddon JA, Hesseling AC, Godfrey-Faussett P, Schaaf HS. 24 September 2013. High treatment success in children treated for multidrug-resistant tuberculosis: an observational cohort study. Thorax. http://dx.doi.org/10.1136/ thoraxjnl-2013-203900.
29. WHO. 2011. Child growth standards. World Health Organization, Geneva, Switzerland. http://www.who.int/childgrowth/standards/weight-for-Age/en/index. html.